Novartis and BMS pause CAR‑T trials after patient deaths while Revolution Medicines gains early FDA approval for pancreatic cancer drug

Novartis has placed several trials of its CAR‑T therapy rapcabtagene autoleucel on hold after three patients receiving the treatment died.

Bristol Myers Squibb also voluntarily froze its autoimmune CAR‑T program using zolacabtagene autoleucel after observing transient, reversible inflammatory events.

Revolution Medicines announced early FDA approval for its pancreatic cancer drug, now called Rasonque, offering a new option for a disease with limited treatments.

BioNTech stopped a mid‑stage trial of its mRNA cancer immunotherapy after a futility analysis showed the study was unlikely to meet its endpoints.

Nine mid‑size biopharma companies joined larger peers in President Donald Trump’s Most Favored Nation drug‑pricing scheme.